- Home
- BRNS vs LTRN Comparison
BRNS vs LTRN Comparison
Compare BRNS & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- LTRN
- Stock Information
- Founded
- BRNS 2016
- LTRN 2013
- Country
- BRNS United Kingdom
- LTRN United States
- Employees
- BRNS N/A
- LTRN N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- LTRN Health Care
- Exchange
- BRNS Nasdaq
- LTRN Nasdaq
- Market Cap
- BRNS 38.7M
- LTRN 37.2M
- IPO Year
- BRNS 2021
- LTRN 2020
- Fundamental
- Price
- BRNS $0.87
- LTRN $3.86
- Analyst Decision
- BRNS Strong Buy
- LTRN Strong Buy
- Analyst Count
- BRNS 2
- LTRN 1
- Target Price
- BRNS $3.00
- LTRN $25.00
- AVG Volume (30 Days)
- BRNS 33.3K
- LTRN 35.5K
- Earning Date
- BRNS 05-07-2025
- LTRN 05-15-2025
- Dividend Yield
- BRNS N/A
- LTRN N/A
- EPS Growth
- BRNS N/A
- LTRN N/A
- EPS
- BRNS N/A
- LTRN N/A
- Revenue
- BRNS $14,969,000.00
- LTRN N/A
- Revenue This Year
- BRNS N/A
- LTRN N/A
- Revenue Next Year
- BRNS N/A
- LTRN N/A
- P/E Ratio
- BRNS N/A
- LTRN N/A
- Revenue Growth
- BRNS 4381.74
- LTRN N/A
- 52 Week Low
- BRNS $0.64
- LTRN $2.55
- 52 Week High
- BRNS $2.45
- LTRN $7.21
- Technical
- Relative Strength Index (RSI)
- BRNS 47.94
- LTRN 52.98
- Support Level
- BRNS $0.80
- LTRN $3.80
- Resistance Level
- BRNS $0.95
- LTRN $4.46
- Average True Range (ATR)
- BRNS 0.12
- LTRN 0.36
- MACD
- BRNS -0.00
- LTRN 0.04
- Stochastic Oscillator
- BRNS 29.70
- LTRN 46.81
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.